Scripps Research Logo

Welcome to the Rosen Laboratory Website!


January 24, 2016 - LAB IN THE NEWS


More uses for MS drug, TSRI study suggests: Ozanimod, discovered at TSRI, may help with other autoimmune diseases CLICK HERE TO GO TO THE ARTICLE


January 22, 2016 - NEW PUBLICATION


Teijaro JR, Studer S, Leaf N, Kiosses WB, Nguyen N, Matsuki K, Negishi H, Taniguchi T, Oldstone MB, Rosen H. (2016) S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification. Proc Natl Acad Sci USA. 2016 Jan 19. pii: 201525356. [Epub ahead of print] PMID: 26787880  CLICK HERE TO READ IT NOW


January 20, 2016 - LAB IN THE NEWS


Fierce Biotech Research - Scripps team spots a new mechanism that drives Celgene's ozanimod, potential rivals  CLICK HERE TO GO TO THE ARTICLE


Additional Information on Ozanimod (RPC1063)

The Molecular Libraries and Imaging Program Continues to Pay Dividends

After Leaving the Common Fund

The Common Fund’s Molecular Libraries and Imaging (MLI) Program has made promising inroads in the development of new therapeutics for human disease. A compound initially discovered by the NIH Molecular Libraries Probe Production Center at The Scripps Research Institute (TSRI), which was a part of the MLI program, was a precursor to the drug candidate ozanimod; which is currently in two Phase III clinical trials –one for patients with relapsing multiple sclerosis and the other in patients with ulcerative colitis. Dr. Hugh Rosen, a professor at TSRI was a Center Principal Investigator...CLICK HERE TO READ ON

Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis


Comprehensive Center for Chemical Probe Discovery and Optimization at TSRI